Remifentanil Protects against Lipopolysaccharide-Induced Inflammation through PARP-1/NF-κB Signaling Pathway

Figure 4

Remifentanil inhibited LPS-induced NF-κB p65 nuclear translocation and expression. (a) RT-PCR of PARP-1 mRNA expression after PARP-1 inhibition by siRNA. (b, c) Western blotting analysis of PARP-1 protein expression after PARP-1 inhibition by siRNA. (d) Immunofluorescence analysis of NF-κB p65 (green) and DAPI (blue). Nuclei were labelled with 4,6-diamidino-2-phenylindole (DAPI) (blue); p65 was stained with rabbit anti-p65 primary antibody and Alexa 488-conjugated goat anti-rabbit second antibody (green). (e, f) Western blotting analysis of NF-κB p65 protein expression. versus control, ^# versus LPS+PBS. si-PARP-1: siRNA of PARP-1; si-NC: negative control of PARP-1 siRNA; PARP-1: poly(ADP-ribose) polymerase 1; LPS: lipopolysaccharide. .

(a)

(b)

(c)

(d)

(e)

(f)